1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1:

Summary of the imaging parameters pre- and postbevacizumab

ParameterPrebevacizumab Mean (SD) × 103Postbevacizumab Mean (SD) × 103P Value (T Value)
EC100%2.52 (0.57)2.43 (0.57).256 (1.15)
EC75%1.91 (0.53)1.77 (0.47).281 (1.08)
EC50%1.51 (0.48)1.38 (0.40).277 (1.11)
EC25%1.06 (0.38)0.98 (0.30).184 (1.35)
FLAIRVOLa121.88 (70.68)77.317 (38.55).002 (4.28)
CEVOLa24.90 (15.26)9.16 (9.17)<.001 (6.34)